由ixekizumab诱导的多重粘膜:一个病例报告
Cheng Zheng1, Xiao He2, Xuxia Tang2
1The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
The Annals of otology, rhinology, and laryngology
|May 14, 2024
概括
作为一种与免疫相关的不良事件,易克西祖马布 (Ixekizumab) 是一种17A型干细胞酶抑制剂,很少会引起多种粘膜. 早期识别和治疗用皮质类固醇和thalidomide解决了患者的症状.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 伊克西祖马布是一种用于治疗牛皮的素-17A抑制剂.
- 常见的副作用包括注射部反应和上呼吸道感染.
- 不常见的不良事件包括炎症性肠病和多重粘膜.
研究的目的:
- 报告多个粘膜的病例作为ixekizumab治疗的不良事件.
- 为了强调识别和管理这种罕见的副作用的重要性.
主要方法:
- 一名51岁的男子在ixekizumab治疗后出现了喉痛和多发性.
- 诊断评估包括灵活的喉腔镜检查.
- 治疗涉及药物停用和启动皮质类固醇和thalidomide.
主要成果:
- 这位患者出现了口腔,耳和表性,对传统治疗没有反应.
- 这些被确定为由ixekizumab引起的与免疫相关的不良事件.
- 在停止使用ixekizumab并开始使用皮质类固醇和thalidomide后,症状消失.
结论:
- 多重粘膜是与ixekizumab相关的潜在的,尽管不常见的不良事件.
- 临床医生应警在接受ixekizumab治疗的患者中出现这种副作用.
- 早期干预对于患者的康复和症状缓解至关重要.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
219
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
219
Inflammatory Bowel Disease I: Ulcerative Colitis
166
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
166
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
113
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
113
Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
450
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
450
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136


